SG Americas Securities LLC Buys 33,375 Shares of BioNTech SE (NASDAQ:BNTX)

SG Americas Securities LLC raised its stake in shares of BioNTech SE (NASDAQ:BNTX) by 412.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 41,470 shares of the company’s stock after buying an additional 33,375 shares during the quarter. SG Americas Securities LLC’s holdings in BioNTech were worth $4,726,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Baillie Gifford & Co. grew its stake in BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after acquiring an additional 31,773 shares in the last quarter. FMR LLC boosted its holdings in BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after purchasing an additional 5,598,190 shares during the period. Fred Alger Management LLC purchased a new position in shares of BioNTech during the 3rd quarter valued at $59,485,000. DekaBank Deutsche Girozentrale increased its holdings in shares of BioNTech by 12.6% in the third quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock worth $56,886,000 after purchasing an additional 53,800 shares during the period. Finally, Point72 Asset Management L.P. raised its position in shares of BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after buying an additional 341,311 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Stock Performance

NASDAQ:BNTX opened at $118.14 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm has a market cap of $28.32 billion, a PE ratio of -56.26 and a beta of 0.18. The business has a 50 day moving average price of $115.78 and a 200-day moving average price of $105.70.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.73 EPS. Equities research analysts predict that BioNTech SE will post -3.77 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on BNTX shares. Canaccord Genuity Group boosted their target price on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research report on Wednesday, November 27th. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. BMO Capital Markets reiterated an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. Berenberg Bank started coverage on shares of BioNTech in a report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target on the stock. Finally, TD Cowen dropped their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.